Medigus
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | 10.1m | 91.9m | 91.7m | - | - |
| % growth | (37 %) | 95 % | 1805 % | 808 % | - | - | - |
| EBITDA | (14.5m) | (7.9m) | (22.2m) | (12.0m) | (12.8m) | - | - |
| % EBITDA margin | (5295 %) | (1485 %) | (220 %) | (13 %) | (14 %) | - | - |
| Profit | (14.2m) | (4.3m) | 6.8m | (9.8m) | (16.0m) | - | - |
| % profit margin | (5193 %) | (815 %) | 67 % | (11 %) | (17 %) | - | - |
| EV / revenue | 26.3x | 56.9x | 2.4x | -0.1x | 0.1x | - | - |
| EV / EBITDA | -0.5x | -3.8x | -1.1x | 0.6x | -0.4x | - | - |
| R&D budget | <1m | <1m | 1.0m | 4.9m | 5.9m | - | - |
| R&D % of revenue | 223 % | 188 % | 10 % | 5 % | 6 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
N/A | Grant | ||
| N/A | $7.0m | Early VC | |
$11.1m | Post IPO Equity | ||
| N/A | $3.0m | Post IPO Equity | |
| N/A | N/A | IPO | |
| Total Funding | AUD10.8m | ||
Related Content
Recent News about Medigus
EditMedigus is a technology company specializing in advanced medical solutions and visual inspection technologies. Operating in the healthcare and industrial sectors, Medigus develops and markets innovative endoscopic devices, such as the MUSE system, which provides minimally invasive treatment for GERD (Gastroesophageal Reflux Disease). The company also offers cutting-edge visual inspection solutions through its subsidiary, ScoutCam, which serves clients in the aerospace, automotive, and industrial markets. Medigus generates revenue through the sale of its medical devices, licensing agreements, and development projects. Key clients include healthcare providers, aerospace companies, and industrial firms. The business model focuses on leveraging proprietary technology and strategic partnerships to drive growth and market penetration.
Keywords: endoscopic devices, GERD treatment, visual inspection, aerospace, automotive, industrial, MUSE system, ScoutCam, minimally invasive, proprietary technology.
